Eglovitch Michelle, Parlier-Ahmad Anna Beth, Legge Catherine, Chithranjan Sajanee, Kolli Saisriya, Violante Stephanie, Dzierzewski Joseph M, Huhn Andrew Stephen, Wilkerson Allison, Martin Caitlin Eileen
Department of Psychology, Virginia Commonwealth University, Richmond, VA, United States.
School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Front Psychiatry. 2023 Sep 14;14:1244156. doi: 10.3389/fpsyt.2023.1244156. eCollection 2023.
Among individuals receiving medication for OUD (MOUD), insomnia is highly prevalent and increases the risk for negative OUD outcomes. However, little is known about MOUD patient-reported preferences for insomnia treatments among women with OUD. This mixed-methods study explored acceptability of and patient preferences for sleep interventions among women in OUD treatment.
This is an analysis from an ongoing cross-sectional survey and interview study investigating the relationship between sleep and OUD recovery. The parent study is actively enrolling non-pregnant women between 18-45 years stabilized on buprenorphine from an outpatient program. Participants complete measures including the Insomnia Severity Index (ISI), with scores of ≥10 identifying clinically significant insomnia symptoms. A sub-sample who met this threshold completed semi-structured interviews. Descriptive statistics were generated for survey responses, and applied thematic analysis was used for interview data.
Participants selected for the qualitative interview ( = 11) highlighted prior positive and negative experiences with sleep treatments, challenges with employing non-pharmacological sleep strategies, and preferences for both medical and behavioral sleep interventions while in recovery. Women emphasized the need for flexibility of sleep therapy sessions to align with ongoing social determinants (e.g., caregiving responsibilities) as well as for sleep medications without sedating effects nor risk of dependency.
Many women receiving MOUD have concomitant insomnia symptoms, and desire availability of both pharmacologic and behavioral sleep interventions within the OUD treatment setting. Qualitative findings underscore the need for evidence-based sleep interventions that account for the unique socioenvironmental factors that may impact strategy implementation in this population.
在接受阿片类物质使用障碍药物治疗(MOUD)的个体中,失眠非常普遍,且会增加阿片类物质使用障碍出现负面结果的风险。然而,对于MOUD患者报告的阿片类物质使用障碍女性失眠治疗偏好知之甚少。这项混合方法研究探讨了阿片类物质使用障碍治疗中女性对睡眠干预的可接受性和患者偏好。
这是一项正在进行的横断面调查和访谈研究的分析,该研究调查睡眠与阿片类物质使用障碍康复之间的关系。母研究正在积极招募来自门诊项目、年龄在18至45岁之间、使用丁丙诺啡病情稳定的非孕妇女性。参与者完成包括失眠严重程度指数(ISI)在内的测量,得分≥10表明存在具有临床意义的失眠症状。达到该阈值的子样本完成了半结构化访谈。对调查回复进行描述性统计,并对访谈数据进行主题分析。
被选入定性访谈的参与者(n = 11)强调了之前睡眠治疗的积极和消极经历、采用非药物睡眠策略的挑战,以及康复期间对药物和行为睡眠干预的偏好。女性强调睡眠治疗课程需要灵活安排,以适应当前的社会决定因素(如照顾责任),以及需要无镇静作用且无依赖风险的睡眠药物。
许多接受MOUD治疗的女性伴有失眠症状,她们希望在阿片类物质使用障碍治疗环境中能获得药物和行为睡眠干预。定性研究结果强调了基于证据的睡眠干预措施的必要性,这些措施要考虑到可能影响该人群策略实施的独特社会环境因素。